From Name:
From Email:
To Name:
To Email:

Optional Message:


New IBD drug, vedolizumab, receives priority review status for ulcerative colitis

from Pharmacy Practice News

Takeda Pharmaceutical Company Ltd. announced that it received priority review status from the FDA for its drug vedolizumab, an investigational antibody for the treatment of adults with moderately to severely active Crohn's disease and ulcerative colitis. Takeda submitted a biologics license application to the FDA for the treatment of CD and UC; the UC application will receive priority review, and the application for CD will be reviewed under the standard timeline. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063